Erectile dysfunction affects more than half of men over the age of forty. Its prevalence rises sharply with age, but lifestyle and underlying health conditions significantly alter individual risk.
Key Takeaways
- Erectile dysfunction is defined as inability to achieve or maintain erection sufficient for satisfactory sexual performance, occurring in >75% of attempts over 3 months
- According to the Massachusetts Male Aging Study (MMAS), the prevalence of minimal, moderate, or complete erectile dysfunction (ED) among men aged 40-70 years is 52%
- PDE5 success drops to 25% in severe cavernosal fibrosis
- Diabetes increases ED risk 3-fold, with 50% prevalence after 10 years
- PDE5 inhibitors like sildenafil effective in 70% overall
Erectile dysfunction affects millions worldwide, yet many men can improve results with effective treatment.
Related reading
01 · Category
Diagnosis and Symptoms25 stats
01
Erectile dysfunction is defined as inability to achieve or maintain erection sufficient for satisfactory sexual performance, occurring in >75% of attempts over 3 months
02
IIEF-5 score <22 indicates ED, with <12 severe, 13-16 moderate, 17-21 mild
03
Nocturnal penile tumescence (NPT) testing shows <1 erection/night or duration <10 min indicates organic ED
04
Penile duplex Doppler ultrasound reveals peak systolic velocity <25 cm/s for arterial insufficiency
05
End-diastolic velocity >5 cm/s on Doppler indicates veno-occlusive dysfunction
06
SHIM questionnaire score of 1-7 is severe ED, 8-11 moderate, 12-16 mild, 17-21 no ED
07
Morning erections absent in 70% of organic ED vs preserved in psychogenic
08
Bulbocavernosus reflex latency >2SD above mean suggests neurogenic ED
09
Vibratory perception threshold >10V at penis indicates neuropathy
10
Serum testosterone <300 ng/dL with symptoms warrants ED workup
11
PSA >4 ng/mL prompts prostate evaluation in ED patients over 50
12
HbA1c >7% correlates with higher ED severity in diabetics
13
Lipid profile: LDL >130 mg/dL increases vascular ED likelihood
14
Penile biothesiometry shows reduced sensitivity in 40% diabetic ED
15
RigiScan records rigidity <70% or tumescence <70% duration indicates ED
16
IIEF-EF domain score classifies ED as none (26-30), mild (22-25), mild-mod (17-21), mod (12-16), severe (1-11)
17
Visual symptoms with PDE5i suggest non-arteritic ischemic optic neuropathy risk
18
Sudden ED onset with normal labs points to psychogenic etiology in 80%
19
Penile curvature >30 degrees on exam suggests Peyronie's
20
Prostate size >30g on DRE correlates with LUTS-ED comorbidity
21
Abnormal anal sphincter tone indicates sacral neuropathy
22
Fasting glucose >126 mg/dL flags undiagnosed diabetes in ED patients
23
SHBG levels adjust free testosterone calculation for accurate hypogonadism dx
24
Pelvic MRI shows cavernosal fibrosis in chronic ED cases
25
EHS (Erection Hardness Score) 0=no, 1=large but not hard, 2=hard but not hard enough, 3=hard enough for penetration, 4=fully hard
Interpretation
Diagnosis and Symptoms Interpretation
While ED can be diagnosed with a bewildering array of scores and scans, it essentially boils down to a simple yet profound struggle: for a significant portion of men, the sophisticated machinery of arousal is consistently failing to deliver a "hard enough for penetration" result, which is less a clinical score and more a deeply personal disappointment.
02 · Category
Prevalence and Epidemiology30 stats
01
According to the Massachusetts Male Aging Study (MMAS), the prevalence of minimal, moderate, or complete erectile dysfunction (ED) among men aged 40-70 years is 52%
02
In the MMAS, complete ED was reported by 10% of men aged 40-70, moderate ED by 25%, and minimal ED by 17%
03
The Cologne Male Survey found that 19.2% of men aged 30-80 in Germany had ED, with prevalence increasing from 2.3% in 30-39 year-olds to 66.2% in 70-80 year-olds
04
A global meta-analysis estimates ED prevalence at 8-23% in men under 40, rising to over 60% in men over 70
05
In the US, approximately 30 million adult men are affected by ED, representing about 10% of the male population over 20
06
The Health Professionals Follow-up Study reported ED prevalence increasing from 32% at age 50 to 75% at age 80 among US men
07
In China, the China Sex Health Survey found 28.1% prevalence of ED in men aged 20-70
08
European Male Aging Study (EMAS) showed 20.8% moderate to severe ED in men aged 40-79 across 8 countries
09
NHANES data indicates 18.4% of US men aged 20+ have ED
10
In Brazil, a national survey reported 45.7% ED prevalence in men over 18
11
UK Biobank study found 12.5% ED prevalence in men aged 40-69
12
In Japan, a survey of 2,419 men showed 5.4%, 20.1%, and 42.3% ED rates for ages 20-29, 40-49, and 60-69 respectively
13
Australian study reported 29.5% ED in men aged 45-64
14
In India, 27.4% of men aged 18-60 reported ED per a multicenter study
15
Italian survey (QuED) found 13% mild, 12% moderate, 8% severe ED in men aged 18-84
16
South Korean study showed ED prevalence of 13.1% in men 30-79
17
In the US, ED affects 1 in 10 men overall, but up to 4 in 10 over 45
18
Global projection estimates 322 million men with ED by 2025, up from 152 million in 1995
19
In diabetic men, ED prevalence is 35-75% vs 15-25% in general population
20
Post-prostatectomy ED rates are 14-90% at 2 years, averaging 59%
21
In hypertensive men, ED prevalence is 23% higher than normotensives
22
MMAS follow-up showed annual ED incidence of 2.6% per year in men 40-79
23
In smokers, ED risk is 1.5-2 times higher, affecting 24% vs 14% non-smokers
24
Obesity triples ED risk, with 41% prevalence in obese vs 24% normal weight men
25
Depression doubles ED prevalence to 40% in affected men
26
In veterans with PTSD, ED prevalence is 39% vs 25% without
27
Racial differences: Black men have 20% higher ED odds than whites per MMAS
28
Hispanic men show 1.3-1.6 times higher ED prevalence than non-Hispanics
29
In men with lower urinary tract symptoms (LUTS), ED prevalence is 50-70%
30
ED prevalence in chronic kidney disease is 40-80%
Interpretation
Prevalence and Epidemiology Interpretation
When you consider that nearly half of all men over forty are contending with some degree of erectile dysfunction, it’s clear this isn't just a rare bedroom hiccup but a widespread, age-accelerating reality that speaks volumes about the intimate intersection of vascular health, lifestyle, and sheer human biology.
03 · Category
Prognosis and Complications23 stats
01
PDE5 success drops to 25% in severe cavernosal fibrosis
02
Untreated ED linked to 44% higher CV event risk within 7 years
03
ED predicts all-cause mortality HR 1.33 in community men
04
Penile prosthesis infection rate 1-3%, revision 5-10% at 5 years
05
PDE5i priapism risk <0.1%, vision loss NAION 2.8/100k vs 11/100k age-matched
06
Alprostadil injection fibrosis 5-10% long-term users
07
TRT increases PSA 0.3-0.5 ng/mL, prostate CA risk not elevated per large trials
08
Severe ED with diabetes has 20% spontaneous recovery rate over 5 years
09
Psychogenic ED remits in 30% without treatment over 1 year
10
Post-prostatectomy potency recovery plateaus at 70% by 24 months with rehab
11
ED treatment adherence drops to 50% at 1 year, 25% at 3 years
12
Partner satisfaction post-prosthesis 82%, but 20% dissatisfaction if not counseled
13
LiSWT durability: 50% maintain benefit at 2 years without boosters
14
Untreated hypogonadism worsens ED progression in 70% over 2 years
15
CV risk reduction with ED Rx initiation: 20% lower MI events
16
Depression risk 2-fold higher in untreated ED men
17
Relationship dissolution 15% higher in couples with untreated ED
18
Penile prosthesis malleable vs inflatable: 85% vs 92% 10-yr survival
19
Sildenafil headache 16%, flushing 10%, dyspepsia 7%, vision changes 3%
20
Tadalafil back pain 8%, myalgia 4%
21
MUSE pain 32%, urethral bleeding 4%
22
ICC injection pain 33%, priapism 0.4%, hematoma 6%
23
Vacuum device pain 20%, pivoting 30%, cold penis 15%
Interpretation
Prognosis and Complications Interpretation
While ED is more than a bedroom issue, its statistics paint a stark, interconnected picture of vascular health, psychological strain, and treatment trade-offs, reminding us that it's a serious condition where ignoring the problem can damage your heart and relationships, but tackling it requires navigating a landscape of imperfect yet often effective options where persistence and shared decision-making are key.
More related reading
04 · Category
Risk Factors and Etiology29 stats
01
Diabetes increases ED risk 3-fold, with 50% prevalence after 10 years
02
Smoking cessation reduces ED risk by 25% within 1 year
03
Each 10 cm increase in waist circumference raises ED risk by 50%
04
Metabolic syndrome confers 2.2-fold ED risk
05
Hyperlipidemia contributes to ED in 43% of cases via endothelial damage
06
Testosterone deficiency (hypogonadism) causes ED in 20-40% of men over 45
07
Peyronie's disease leads to ED in 30-50% of cases due to curvature
08
Chronic opioid use increases ED risk 2-3 fold via hormonal disruption
09
Pelvic surgery (prostatectomy) causes ED in 60-80% due to nerve damage
10
Radiotherapy for prostate cancer results in ED in 30-70% at 5 years
11
Antidepressant SSRIs cause ED in 30-50% of users
12
Beta-blockers induce ED in 10-30% of hypertensive patients
13
Alcoholism leads to ED in 50-70% via neuropathy and liver damage
14
Cycling >3 hours/week raises ED risk 1.7-fold from perineal pressure
15
Parkinson's disease patients have 50-80% ED prevalence
16
Multiple sclerosis causes ED in 50-90% due to spinal cord involvement
17
Spinal cord injury results in ED in 75% of cases
18
Atherosclerosis accounts for 40% of organic ED cases via vascular occlusion
19
Venous leak (corporal veno-occlusive dysfunction) causes 20-30% of vasculogenic ED
20
Cavernosal artery insufficiency seen in 80% of diabetic ED patients
21
Psychological stress contributes to 10-20% of ED cases acutely
22
Performance anxiety perpetuates 30% of psychogenic ED cycles
23
Relationship discord increases ED risk 2-fold in partnered men
24
Childhood sexual abuse history raises ED odds 3-fold
25
ED onset before 40 often signals cardiovascular disease in 30% cases
26
Sleep apnea increases ED risk 2.5-fold via hypoxia
27
BPH medications (5-ARIs) cause ED in 5-15% users
28
Penile fracture leads to ED in 10-50% due to fibrosis
29
Priapism >4 hours causes ED in 30-90% from ischemia
Interpretation
Risk Factors and Etiology Interpretation
The human body, in its infinite wisdom, has provided a startlingly clear and interconnected report card: nearly every bad habit, chronic condition, and physical trauma will, with remarkable consistency, send its regrets directly to your penis.
05 · Category
Treatment Options28 stats
01
PDE5 inhibitors like sildenafil effective in 70% overall
02
Sildenafil 50mg improves erections in 74% vs 19% placebo
03
Tadalafil 20mg allows intercourse up to 36 hours, efficacy 81% vs 30% placebo
04
Vardenafil 10mg success rate 80% in diabetics
05
Avanafil 200mg onset in 15 min, efficacy 71% vs 27% placebo
06
Intraurethral alprostadil (MUSE) effective in 43% vs 17% placebo
07
Intracavernosal PGE1 (Caverject) 20mcg success 85% in organic ED
08
Vacuum erection devices achieve rigidity in 90%, satisfaction 60-80%
09
Penile prosthesis implantation has 92-98% mechanical survival at 5 years
10
Inflatable penile prosthesis (IPP) satisfaction 90-95% in patients, 80-90% partners
11
Low-intensity shockwave therapy (LiSWT) improves IIEF by 5-7 points in 60%
12
Testosterone replacement therapy (TRT) benefits ED in 60% hypogonadal men
13
Topical alprostadil (Vitaros) efficacy 52% vs 19% placebo
14
Cognitive behavioral therapy (CBT) resolves psychogenic ED in 60-90%
15
Couples sex therapy improves outcomes in 70% discordant pairs
16
Lifestyle modification (weight loss 10%) reverses ED in 30% obese men
17
Smoking cessation improves ED in 25% within 6 months
18
Pelvic floor exercises (Kegels) enhance PDE5i response by 40%
19
Stem cell therapy trials show 70% IIEF improvement at 6 months
20
Platelet-rich plasma (PRP) injections yield 50-60% satisfaction in mild ED
21
Gene therapy (hMaxi-K) phase I safe, 2/3 improved erections
22
Combination PDE5i + alprostadil boosts efficacy to 90% in refractory ED
23
Nerve-sparing prostatectomy preserves potency in 60-80% young men
24
PDE5i post-prostatectomy recovers function in 50% at 2 years
25
Penile rehab protocol (nightly tadalafil) potency recovery 52% vs 24% placebo
26
Botulinum toxin A intracavernosal relaxes smooth muscle, 60% improvement mild ED
27
Mindfulness-based stress reduction aids psychogenic ED in 65%
28
Bariatric surgery reverses ED in 40% morbidly obese men at 1 year
Interpretation
Treatment Options Interpretation
While our pharmaceutical toolbox is impressively stocked—with pills offering everything from rapid onset to marathon sessions, injections reaching heroic success rates, and devices with near-perfect mechanical reliability—the persistent power of lifestyle changes, psychological support, and even simple pelvic floor exercises reminds us that the most effective treatment plan often starts with the whole human, not just the part.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lars Eriksen. (2026, February 13). Erectile Dysfunction Statistics. Gitnux. https://gitnux.org/erectile-dysfunction-statistics
MLA
Lars Eriksen. "Erectile Dysfunction Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/erectile-dysfunction-statistics.
Chicago
Lars Eriksen. 2026. "Erectile Dysfunction Statistics." Gitnux. https://gitnux.org/erectile-dysfunction-statistics.
Sources & references
3 datasets cited across this report · attribution is report-level